Published in Vaccine Weekly, October 25th, 1999
A major recent advance comes from a German research group that finally has figured out a way to use liver-infecting viruses (hepadnaviruses such as hepatitis B virus) as a vector. But serious practical obstacles remain, warns Don Ganem of the Howard Hughes Medical Institute.
"We are therefore, still a long way from the routine use of hepadnaviruses in gene therapy," Ganem wrote in a commentary article that appeared in the Proceedings of the National Academy of Sciences ("An Advance in Liver-Specific Gene Delivery," PNAS,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.